AC Immune (ACIU) Competitors $2.10 -0.04 (-1.87%) Closing price 03:58 PM EasternExtended Trading$2.12 +0.02 (+0.71%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACIU vs. MLYS, IMNM, ZYME, ATAI, URGN, OCS, ORIC, NUVB, SION, and NAGEShould you be buying AC Immune stock or one of its competitors? The main competitors of AC Immune include Mineralys Therapeutics (MLYS), Immunome (IMNM), Zymeworks (ZYME), atai Life Sciences (ATAI), Urogen Pharma (URGN), Oculis (OCS), Oric Pharmaceuticals (ORIC), Nuvation Bio (NUVB), Sionna Therapeutics (SION), and Niagen Bioscience (NAGE). These companies are all part of the "pharmaceutical products" industry. AC Immune vs. Its Competitors Mineralys Therapeutics Immunome Zymeworks atai Life Sciences Urogen Pharma Oculis Oric Pharmaceuticals Nuvation Bio Sionna Therapeutics Niagen Bioscience AC Immune (NASDAQ:ACIU) and Mineralys Therapeutics (NASDAQ:MLYS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk. Does the media favor ACIU or MLYS? In the previous week, Mineralys Therapeutics had 20 more articles in the media than AC Immune. MarketBeat recorded 20 mentions for Mineralys Therapeutics and 0 mentions for AC Immune. Mineralys Therapeutics' average media sentiment score of 0.98 beat AC Immune's score of 0.00 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment AC Immune Neutral Mineralys Therapeutics Positive Do analysts recommend ACIU or MLYS? AC Immune presently has a consensus price target of $12.00, suggesting a potential upside of 471.43%. Mineralys Therapeutics has a consensus price target of $32.25, suggesting a potential upside of 120.89%. Given AC Immune's stronger consensus rating and higher probable upside, research analysts plainly believe AC Immune is more favorable than Mineralys Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AC Immune 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Mineralys Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Is ACIU or MLYS more profitable? Mineralys Therapeutics has a net margin of 0.00% compared to AC Immune's net margin of -174.94%. AC Immune's return on equity of -49.35% beat Mineralys Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets AC Immune-174.94% -49.35% -23.16% Mineralys Therapeutics N/A -70.44%-65.51% Which has more volatility & risk, ACIU or MLYS? AC Immune has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of -0.29, meaning that its stock price is 129% less volatile than the S&P 500. Which has stronger valuation and earnings, ACIU or MLYS? AC Immune has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAC Immune$31.02M6.80-$57.83M-$0.58-3.62Mineralys TherapeuticsN/AN/A-$177.81M-$3.56-4.10 Do institutionals and insiders hold more shares of ACIU or MLYS? 51.4% of AC Immune shares are held by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are held by institutional investors. 4.6% of AC Immune shares are held by insiders. Comparatively, 25.6% of Mineralys Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryAC Immune beats Mineralys Therapeutics on 9 of the 15 factors compared between the two stocks. Get AC Immune News Delivered to You Automatically Sign up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACIU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACIU vs. The Competition Export to ExcelMetricAC ImmuneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$210.86M$3.11B$5.74B$9.56BDividend YieldN/A2.23%4.53%4.07%P/E Ratio-3.6220.3730.4325.14Price / Sales6.80238.33392.4187.63Price / CashN/A42.3737.0358.50Price / Book2.337.918.956.21Net Income-$57.83M-$54.72M$3.26B$265.38M7 Day Performance-1.41%1.58%1.03%-1.12%1 Month Performance0.96%5.81%4.28%-0.68%1 Year Performance-37.50%8.71%28.38%18.92% AC Immune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACIUAC Immune1.715 of 5 stars$2.10-1.9%$12.00+471.4%-36.7%$210.86M$31.02M-3.62140Positive NewsMLYSMineralys Therapeutics3.2179 of 5 stars$13.19+1.5%$32.25+144.5%+47.1%$847.28MN/A-3.5428IMNMImmunome1.8463 of 5 stars$9.66-0.3%$23.14+139.6%-37.1%$843.47M$9.04M-3.1440ZYMEZymeworks0.3748 of 5 stars$12.44+3.5%N/AN/A$837.60M$76.30M-12.82460ATAIatai Life Sciences2.8389 of 5 stars$3.96-4.1%$11.25+184.1%+203.1%$827.39M$310K-4.3580Earnings ReportAnalyst RevisionURGNUrogen Pharma4.5756 of 5 stars$18.24+2.8%$31.43+72.3%+28.7%$820.96M$90.40M-5.49200Analyst ForecastOCSOculis3.1126 of 5 stars$17.97-1.3%$35.33+96.6%+46.5%$795.09M$780K-6.812News CoveragePositive NewsORICOric Pharmaceuticals4.7276 of 5 stars$9.20-0.4%$18.57+101.9%-3.5%$787.47MN/A-4.9280Short Interest ↓Analyst RevisionNUVBNuvation Bio2.2742 of 5 stars$2.24-2.8%$7.33+228.1%-5.7%$782.60M$7.87M-3.5560SIONSionna Therapeutics1.9151 of 5 stars$20.03+13.4%$38.50+92.2%N/A$779.68MN/A0.0035Positive NewsGap UpNAGENiagen Bioscience1.3448 of 5 stars$9.82+0.9%$13.42+36.7%N/A$776M$99.60M46.76120 Related Companies and Tools Related Companies Mineralys Therapeutics Competitors Immunome Competitors Zymeworks Competitors atai Life Sciences Competitors Urogen Pharma Competitors Oculis Competitors Oric Pharmaceuticals Competitors Nuvation Bio Competitors Sionna Therapeutics Competitors Niagen Bioscience Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACIU) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AC Immune Please log in to your account or sign up in order to add this asset to your watchlist. Share AC Immune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access